Clinical Trials
As part of our mission to deliver the latest medical breakthroughs, CSSIFM physicians conduct clinical trials that test new treatments for a wide range of patients and cancer types. The following trials are being conducted at CSSIFM and new ones are on the horizon. Please fill out the Clinical Trial Inquiry to get more information.
Indication: Pancreatic Cancer
NCT04390399 | Quilt-88
Link to clinicaltrials.gov
https://clinicaltrials.gov/ct2/show/NCT04390399
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Primary purpose of this study:
The purpose of this study is to obtain initial comparative efficacy, by progression-free survival (PFS) in the first-line maintenance phase setting and second-line setting for standard-of-care chemotherapy in combination with immunotherapy in subjects with locally advanced or metastatic pancreatic cancer
Indication: Solid Tumors
NCT04898543 | Quilt-3.076
Link to clinicaltrials.gov
https://clinicaltrials.gov/ct2/show/NCT04898543
Phase 1 open-label study of autologous Memory-Cytokine Enriched Natural Killer (M-CENK) cells in subjects with locally advanced or metastatic solid tumors
Primary purpose of this study:
The primary purpose of this study is to evaluate the overall safety profile of M-CENK for intravenous and N-803 for subcutaneous administration after the first dose of M-CENK and the first dose of N-803 (treatment cycle 1, Day 1) in subjects with relapsed or refractory (R/R) solid tumor malignancies
Clinical Trial Inquiry
El Segundo
As part of our mission to deliver the latest medical breakthroughs, CSSIFM physicians conduct clinical trials that test new treatments for a wide range of patients and cancer types. The following trials are being conducted at CSSIFM and new ones are on the horizon. Please fill out the Clinical Trial Inquiry to get more information.
Clinical Trial Inquiry
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Indication: Pancreatic Cancer
NCT04390399 | Quilt-88
Link to clinicaltrials.gov
https://clinicaltrials.gov/ct2/show/NCT04390399
Primary purpose of this study:
The purpose of this study is to obtain initial comparative efficacy, by progression-free survival (PFS) in the first-line maintenance phase setting and second-line setting for standard-of-care chemotherapy in combination with immunotherapy in subjects with locally advanced or metastatic pancreatic cancer
Phase 1 open-label study of autologous Memory-Cytokine Enriched Natural Killer (M-CENK) cells in subjects with locally advanced or metastatic solid tumors
Indication: Solid Tumors
NCT04898543 | Quilt-3.076
Link to clinicaltrials.gov
https://clinicaltrials.gov/ct2/show/NCT04898543
Primary purpose of this study:
The primary purpose of this study is to evaluate the overall safety profile of M-CENK for intravenous and N-803 for subcutaneous administration after the first dose of M-CENK and the first dose of N-803 (treatment cycle 1, Day 1) in subjects with relapsed or refractory (R/R) solid tumor malignancies
Clinical Trials